P30GM149408

Center for Molecular Epidemiology - Abstract

The field of epidemiology has gained increasing prominence in the research community and became a household word in 2020. Epidemiology provides the tools to uncover the underlying causes of human illness and to, in turn, inform clinical practice and preventive strategies, advise policy and regulatory actions, and move scientific advancements forward.

In phases I and II, our Centers of Biomedical Research Excellence (COBRE) Center for Molecular Epidemiology at Dartmouth has effectively advanced research in the field. As the only Center for Molecular Epidemiology in Northern New England and one of the only COBRE programs with this focus nationally, we have successfully recruited and mentored the next generation of independent early career investigators. We further supported established investigators to enlarge their research programs, form new collaborations, and integrate the latest biomedical discoveries, innovations, and methods. In doing so, we dramatically grew our research productivity and grant portfolio, as evidenced by the steep rise in the number of publications, presentations, and grants awarded since the inception of our COBRE Center.

As part of achieving sustainability, we formed a new Department of Epidemiology and developed innovative cross-disciplinary training grants. Our cohesive center brings together talented investigators focusing on:

1) Applying new scientific discoveries and technologies to address major human health concerns,
2) Identifying early indicators of disease pathogenesis, and
3) Exploring common pathways of disease etiology and progression in human populations, including those related to health inequities.

In this Phase III application, we will progress our molecular epidemiology research infrastructure forward to full independence and sustainability. Specifically, we will:

1) Evolve a state-of-the-art biorepository and biospecimen resource facility core that supplies the critical services responsive to the ongoing and future needs of biomedical scientists,
2) Expand the pipeline of talented, diverse molecular epidemiologists and provide the requisite mentorship, career development, and research resources to cultivate cutting-edge research and make investigators competitive for NIH funding, and
3) Enhance the governance structure, implementation approaches, stakeholder engagement, and evaluation that will strengthen our center's impact, promote its strategic vision, and forge ties with regional and national partners.

Our success in Phases I and II, combined with strong institutional support, positions us to serve as a vital resource in molecular epidemiology for Northern New England, for COBRE and Idea Networks of Biomedical Research Excellence (INBRE) programs, and more broadly.

Trustees Of Dartmouth College

THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) SUPPORTS BASIC RESEARCH THAT INCREASES OUR UNDERSTANDING OF BIOLOGICAL PROCESSES AND LAYS THE FOUNDATION FOR ADVANCES IN DISEASE DIAGNOSIS, TREATMENT, AND PREVENTION. NIGMS ALSO SUPPORTS RESEARCH IN SPECIFIC CLINICAL AREAS THAT AFFECT MULTIPLE ORGAN SYSTEMS: ANESTHESIOLOGY AND PERI-OPERATIVE PAIN, CLINICAL PHARMACOLOGY ?COMMON TO MULTIPLE DRUGS AND TREATMENTS, AND INJURY, CRITICAL ILLNESS, SEPSIS, AND WOUND HEALING.? NIGMS-FUNDED SCIENTISTS INVESTIGATE HOW LIVING SYSTEMS WORK AT A RANGE OF LEVELSFROM MOLECULES AND CELLS TO TISSUES AND ORGANSIN RESEARCH ORGANISMS, HUMANS, AND POPULATIONS. ADDITIONALLY, TO ENSURE THE VITALITY AND CONTINUED PRODUCTIVITY OF THE RESEARCH ENTERPRISE, NIGMS PROVIDES LEADERSHIP IN SUPPORTING THE TRAINING OF THE NEXT GENERATION OF SCIENTISTS, ENHANCING THE DIVERSITY OF THE SCIENTIFIC WORKFORCE, AND DEVELOPING RESEARCH CAPACITY THROUGHOUT THE COUNTRY.

93.859 - Biomedical Research and Research Training

National Institute of General Medical Sciences (NIGMS) [HHS - NIH]

Lebanon, New Hampshire 03756 United States

Single Zip Code

Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase III - Transitional Centers (P30 Clinical Trial Optional) (PAR-20-115)

Amendment Since initial award the total obligations have increased 219% from $1,230,753 to $3,920,403.